​​Sequencing Therapies in R/R Mantle Cell Lymphoma

Commentary
Video

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Craig A. Portell, MD, associate professor of medicine at University of Virginia, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology (SOHO) Annual Meeting.

      According to Portell, as more is learned about Bruton’s tyrosine kinase (BTK) inhibitor resistance, it can be a challenge to know what to do afterwards. He adds that the chimeric antigen receptor (CAR) T-cell therapy space has been very helpful with this.

      He also remains hopeful that more data on bispecific antibodies, covalent BTK inhibitors, venetoclax (Venclexta), etc., all of which are hard to know how to sequence, will continue to help address challenges in the field of relapsed/refractory mantle cell lymphoma.

      Further, Portell offers some insights on what one can expect from this session at SOHO, as well as additional sessions that are of particular interest to him and colleagues.

      Transcription:

      0:09 | So, today I am going to be talking about sequencing therapies in relapsed mantle cell lymphoma. [We are] starting first with patients, whether they have been exposed to BTK inhibitors or not, and how that may impact the decision making, and then, after exposure to BTK inhibitors, how to fit CAR T-cell therapy in vs a non covalent BTK inhibitor, and [we will] talk about some special scenarios, particularly with p53-mutated relapse disease.

      0:39 | [We will be] really going through the pathways of when a patient would relapse in various different scenarios. So, hopefully that will be informative and give some suggestions about how to manage patients in certain scenarios after progression with various different disease characteristics.

      0:59 | [Overall], the lymphoma sessions, I think, in general, are going to be very well reviewed and thoughtful. So, I am looking forward to hearing what my colleagues have to say.



      Related Content